drugset / Trial / NCT06888492

To Evaluate the Safety and Preliminary Efficacy of Intravitreal EXG202 Injection in Patients with Wet (neovascular) Age-related Macular Degeneration (wAMD)

NCT06888492 ↗

Phase 0 Not yet recruiting 8 enrolled Guangzhou Jiayin Biotech Ltd
Non-randomizedSequentialOpen-labelTreatment

Summary

The goal of this clinical trial is to evaluate the safety, tolerability and efficacy of intravitreal injection of EXG202 in subjects with neovascular age-related Macular Degeneration (nAMD).

Timeline

Start
2025-03-28
Primary completion
2026-04-25
Completion
2026-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject EXG202 Gene therapy (AAV / viral vector) — Intravitreal